E. Monturus

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

R. Gelber, M. Piccart, G. Viale, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos

R. Gelber, M. Piccart, G. Viale, 2020 .

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

S. Kuemmel, E. Hitre, J. Pérez-García, 2021, Breast Cancer Research and Treatment.

Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study

E. Hitre, S. Kümmel, B. Karaszewska, 2020 .

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Sung-Bae Kim, A. Schneeweiss, S. Loi, 2020, The Lancet. Oncology.

ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.

S. Loi, Yeon-Hee Park, N. Harbeck, 2022, Future oncology.

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

Sung-Bae Kim, A. Schneeweiss, S. Swain, 2019, Journal of Clinical Oncology.